Generate QR code
Open Access
Subscription Access
Age, gender aspects of nervous system damage in hiv infection and modern treatment options
https://doi.org/10.30629/0023-2149-2025-103-4-263-271
Abstract
Infection caused by the human immunodefi ciency virus (HIV) has become a signifi cant issue in practical healthcare worldwide and requires a multidisciplinary approach even at the early stages of the disease. The range of systems and organs involved in the pathological process of HIV infection is extensive, with particular attention in clinical practice given to nervous system damage. The treatment of HIV infection has evolved since the introduction of combination antiretroviral therapy (ART) in the 1990s, providing HIV-infected individuals with approaches that ensure viral replication suppression, prevention of acquired immunodefi ciency syndrome (AIDS) throughout their lives through continuous therapy, and interruption of HIV transmission. However, despite the success of these treatment regimens, the global HIV epidemic persists, prompting comprehensive exploration of potential HIV treatment strategies. Currently, modern antiretroviral drugs are widely implemented, leading to a signifi cant increase in the life expectancy of HIV-infected individuals. With the reduction of HIV-related mortality, HIVassociated neurocognitive disorders (HAND) have gained particular importance, as they can develop even in the context of eff ective therapy. The overall prevalence of this pathology among HIV patients reaches up to 42.6%, while treatment options remain a subject of discussion. This article presents a review of contemporary literature dedicated to nervous system damage in HIV infection and current strategies for antiviral therapy selection.
About the Authors
F. A. Yusupov
Osh State University
Kyrgyzstan
Kyrgyzstan
Furkat A. Yusupov — Doctor of Medical Sciences, Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry, Faculty of Medicine
Osh
I. T. Ydyrysov
Osh State University
Kyrgyzstan
Kyrgyzstan
Ismatilla T. Ydyrysov — Doctor of Medical Sciences, Professor, Dean of the Medical Faculty
Osh
A. A. Yuldashev
Osh State University
Kyrgyzstan
Kyrgyzstan
Akmal A. Yuldashev — postgraduate student of the Department of Neurology, Neurosurgery and Psychiatry of the Medical Faculty
Osh
References
1. Xiong L., Loo N.N., Lu Z.Q. et al. Ureterolithiasis in Human Immunodefi ciency Virus (HIV) Patients Treated with Single-Use Ureteroscope: A Case Report. Am. J. Case Rep. 2022;23:e938608. DOI: 10.12659/AJCR.938608
2. Woolhouse M.E.J., Brierley L. Epidemiological characteristics of human-infective RNA viruses. Sci. Data. 2018 Feb 20;5:180017. DOI: 10.1038/sdata.2018.17. PMID: 29461515; PMCID: PMC5819479.
3. Zhang F., Chase-Topping M., Guo C.G., van Bunnik B.A.D., Brierley L., Woolhouse M.E.J. Global discovery of human infective RNA viruses: A modelling analysis. PLoS Pathog. 2020;16(11):e1009079. DOI: 10.1371/journal.ppat.1009079. PMID: 33253277; PMCID: PMC7728385.
4. Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A., Yusupov F.A., Schastylenko A.I. Kidney and central nervous system damage in HIV infection as an interdisciplinary problem. Medical business. 2020;4. (In Russian). DOI: 10.24412/2071-5315-2020-12278
5. Murphy K., Weaver C. Janeway Immunologie. Springer-Spektrum. Berlin/Heidelberg, Germany. Das erworbene Immunschwäche-syndrom (AIDS). 2018;743–749.
6. Shaw G.M., Hunter E. HIV transmission. Cold Spring. Harb. Perspect. Med. 2012;2(11):a006965. DOI: 10.1101/cshperspect.a006965. PMID: 23043157; PMCID: PMC3543106.
7. Brandt L., Angelino P., Martinez R., Cristinelli S., CiuffiA. Sex and Age Impact CD4+ T Cell Susceptibility to HIV In Vitro through Cell Activation Dynamics. Cells. 2023;12(23):2689. DOI: 10.3390/cells12232689. PMID: 38067117; PMCID: PMC10706042.
8. Klein S.L., Flanagan K.L. Sex diff erences in immune responses. Nat. Rev. Immunol. 2016;16(10):626–38. DOI: 10.1038/nri.2016.90. Epub 2016 Aug 22. PMID: 27546235.
9. Wilkinson N.M., Chen H.C., Lechner M.G., Su M.A. Sex diff erences in immunity. Ann. Rev. Immunol. 2022;40:75–94. DOI: 10.1146/annurev-immunol-101320-125133. Epub 2022 Jan 5. PMID: 34985929; PMCID: PMC9805670.
10. Jacobsen H., Klein S.L. Sex diff erences in immunity to viral infections. Front Immunol. 2021;12:720952. DOI: 10.3389/fimmu.2021.720952. PMID: 34531867; PMCID: PMC8438138.
11. Boissier J., Chlichlia K., Digon Y., Ruppel A., Moné H. Preliminary study on sex-related infl ammatory reactions in mice infected with Schistosoma mansoni. Parasitol. Res. 2003;91(2):144–50. DOI: 10.1007/s00436-003-0943-1. Epub 2003 Aug 9. PMID: 12910415.
12. Xia H.J., Zhang G.H., Wang R.R., Zheng Y.T. The infl uence of age and sex on the cell counts of peripheral blood leukocyte subpopulations in Chinese rhesus macaques. Cell Mol. Immunol. 2009;6(6):433–40. DOI: 10.1038/cmi.2009.55. PMID: 20003819; PMCID: PMC4003037.
13. Szaniawski M.A., Spivak A.M., Bosque A., Planelles V. Sex Influences SAMHD1 activity and susceptibility to human immunodefi ciency virus-1 in primary human macrophages. J. Infect. Dis. 2019;219(5):777–785. DOI: 10.1093/infdis/jiy583. PMID: 30299483; PMCID: PMC6376916.
14. Farzadegan H., Hoover D.R., Astemborski J., Lyles C.M., Margolick J.B., Markham R.B., Quinn T.C., Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352(9139):1510–4. DOI: 10.1016/S0140-6736(98)02372-1. PMID: 9820299.
15. Abdullah M., Chai P.S., Chong M.Y., Tohit E.R., Ramasamy R., Pei C.P., Vidyadaran S. Gender eff ect on in vitro lymphocyte subset levels of healthy individuals. Cell Immunol. 2012;272(2):214–9. DOI: 10.1016/j.cellimm.2011.10.009. Epub 2011 Oct 25. PMID: 22078320.
16. Amadori A., Zamarchi R., De Silvestro G., Forza G., Cavatton G., Danieli G.A., Clementi M., Chieco-Bianchi L. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat. Med. 1995;1(12):1279–83. DOI: 10.1038/nm1295-1279. PMID: 7489409.
17. Lee B.W., Yap H.K., Chew F.T., Quah T.C., Prabhakaran K., Chan G.S. et al. Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. Cytometry. 1996;26(1):8–15. DOI: 10.1002/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E. PMID: 8809475.
18. Lisse I.M., Aaby P., Whittle H., Jensen H., Engelmann M., Christensen L.B. T-lymphocyte subsets in West African children: impact of age, sex, and season. J. Pediatr. 1997;130(1):77–85. DOI: 10.1016/s0022-3476(97)70313-5. PMID: 9003854.
19. Uppal S.S., Verma S., Dhot P.S. Normal values of CD4 and CD8 lymphocyte subsets in healthy indian adults and the eff ects of sex, age, ethnicity, and smoking. Cytometry B. Clin. Cytom. 2003;52(1):32–6. DOI: 10.1002/cyto.b.10011. PMID: 12599179.
20. Teixeira D., Longo-Maugeri I.M., Santos J.L., Duarte Y.A., Lebrão M.L., Bueno V. Evaluation of lymphocyte levels in a random sample of 218 elderly individuals from São Paulo city. Rev. Bras. Hematol. Hemoter. 2011;33(5):367–71. DOI: 10.5581/1516-8484.20110100. PMID: 23049341; PMCID: PMC3415787.
21. Matveev A.V., Krasheninnikov A.E., Egorova E.A., Konyaeva E.I. Monitoring the safety of antiretroviral drugs in patients with HIV infection. HIV infection and immunosuppression. 2021;13(1):115–123. (In Russian). DOI: 10.22328/2077-9828-2021-13-1-115-123
22. Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134(17):1385–1394. DOI: 10.1182/blood-2018-01-791400. PMID: 30992269; PMCID: PMC7493463.
23. Hazleton J.E., Berman J.W., Eugenin E.A. Novel mechanisms of central nervous system damage in HIV infection. HIV AIDS (Auckl). 2010;2:39–49. DOI: 10.2147/hiv.s9186. Epub 2010 Mar 11. PMID: 22096383; PMCID: PMC3218694.
24. Raff e S., Sabin C., Gilleece Y. Women Against Viruses in Europe (WAVE), European AIDS Clinical Society. Comorbidities in women living with HIV: A systematic review. HIV Med. 2022;23(4):331-361. DOI: 10.1111/hiv.13240. Epub 2022 Mar 3. PMID: 35243744; PMCID: PMC9311813.
25. Buckner C.M., Luers A.J., Calderon T.M., Eugenin E.A., Berman J.W. Neuroimmunity and the blood–brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. J. Neuroimmune Pharmacol. 2006;1(2):160-81. DOI: 10.1007/s11481–006–9017–3. Epub 2006 Apr 13. PMID: 18040782; PMCID: PMC4359614.
26. Churchill M.J., Wesselingh S.L., Cowley D., Pardo C.A., McArthur J.C., Brew B.J., Gorry P.R. Extensive astrocyte infection is prominent in human immunodefi ciency virus-associated dementia. Ann. Neurol. 2009;66(2):253–8. DOI: 10.1002/ana.21697. PMID: 19743454.
27. Bilimoria PM., Stevens B. Microglia function during brain development: New insights from animal models. Brain Res. 2015;1617:7–17. DOI: 10.1016/j.brainres.2014.11.032. Epub 2014 Nov 26. PMID: 25463024.
28. Gomez Perdiguero E., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L. et al. Tissue-resident macrophages originate from yolk-sacderived erythro-myeloid progenitors. Nature. 2015;518(7540):547-51. DOI: 10.1038/nature13989. Epub 2014 Dec 3. PMID: 25470051; PMCID: PMC5997177.
29. Réu P., Khosravi A., Bernard S., Mold J.E., Salehpour M., Alkass K. et al. The Lifespan and turnover of microglia in the human brain. Cell Rep. 2017;20(4):779–784. DOI: 10.1016/j.celrep.2017.07.004. PMID: 28746864; PMCID: PMC5540680.
30. Salter M.W., Stevens B. Microglia emerge as central players in brain disease. Nat. Med. 2017;23(9):1018–1027. DOI: 10.1038/nm.4397. PMID: 28886007.
31. Gisslén M., Heslegrave A., Veleva E., Yilmaz A., Andersson L.M. et al. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurol. Neuroimmunol. Neuroinfl amm. 2018;6(1):e512. DOI: 10.1212/NXI.0000000000000512. PMID: 30568991; PMCID: PMC6278890.
32. Kumar A., Abbas W., Herbein G. HIV-1 latency in monocytes/macrophages. Viruses. 2014;6(4):1837–60. DOI: 10.3390/v6041837. PMID: 24759213; PMCID: PMC4014723.
33. Le Douce V., Herbein G., Rohr O., Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology. 2010;7:32. DOI: 10.1186/1742–4690–7–32. PMID: 20380694; PMCID: PMC2873506.
34. Cao Y., Lei X., Ribeiro R.M., Perelson A.S., Liang J. Probabilistic control of HIV latency and transactivation by the Tat gene circuit. Proc. Natl. Acad. Sci. U S A. 2018;115(49):12453–12458. DOI: 10.1073/pnas.1811195115. PMID: 30455316; PMCID: PMC6298123.
35. Wallet C., De Rovere M., Van Assche J., Daouad F., De Wit S., Gautier V., Mallon P.W.G., Marcello A., Van Lint C., Rohr O., Schwartz C. Microglial Cells: The Main HIV–1 Reservoir in the Brain. Front. Cell. Infect. Microbiol. 2019;9:362. DOI: 10.3389/fcimb.2019.00362. PMID: 31709195; PMCID: PMC6821723
36. Bogorodskaya M., Chow F.C., Triant V.A. Stroke in HIV. Can. J. Cardiol. 2019;35(3):280–287. DOI: 10.1016/j.cjca.2018.11.032. PMID: 30825950; PMCID: PMC6400325
37. Womack J.A., Chang C.C., So–Armah K.A., Alcorn C., Baker J.V., Brown S.T. et al. HIV infection and cardiovascular disease in women. J. Am. Heart Assoc. 2014;3(5):e001035. DOI: 10.1161/JAHA.114.001035. PMID: 25324353; PMCID: PMC4323817
38. Stone L., Looby S.E., Zanni M.V. Cardiovascular disease risk among women living with HIV in North America and Europe. Curr. Opin. HIV AIDS. 2017;12(6):585–593. DOI: 10.1097/COH.0000000000000413. PMID: 28832367; PMCID: PMC6002961
39. Johnson W., Onuma O., Owolabi M., Sachdev S. Stroke: a global response is needed. Bull World Health Organ. 2016;94(9):634-634A. DOI: 10.2471/BLT.16.181636. PMID: 27708464; PMCID: PMC5034645
40. Koethe J.R., Jenkins C.A., Lau B., Shepherd B.E., Justice A.C., Tate J.P. et al. North American AIDS cohort collaboration on research and design (NA-ACCORD). Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res. Hum. Retroviruses. 2016;32(1):50–8. DOI: 10.1089/aid.2015.0147. Epub 2015 Sep 9. PMID: 26352511; PMCID: PMC4692122
41. Sabin C.A., Ryom L., De Wit S., Mocroft A., Phillips A.N., Worm S.W. et al., D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27(17):2735–48. DOI: 10.1097/01.aids.0000432457.91228.f3. PMID: 23842128
42. Sico J.J., Chang C.C., So–Armah K., Justice A.C., Hylek E., Skanderson M. et al. Veterans Aging Cohort Study. HIV status and the risk of ischemic stroke among men. Neurology. 2015;84(19):1933-40. DOI: 10.1212/WNL.0000000000001560. Epub 2015 Apr 10. PMID: 25862803; PMCID: PMC4433456
43. Chow F.C., Wilson M.R., Wu K., Ellis R.J., Bosch R.J., Linas B.P. Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. AIDS. 2018;32(9):1125–1135. DOI: 10.1097/QAD.0000000000001799. PMID: 29746317; PMCID: PMC5955006.
44. Moulignier A., Savatovsky J., Assoumou L., Lescure F.X., Lamirel C., Godin O. et al. Microvascular brain retina and kidney (MicroBREAK) Study Group. Silent cerebral small–vessel disease is twice as prevalent in middle–aged individuals with well–controlled, combination antiretroviral therapy-treated human immunodefi ciency virus (HIV) Than in HIV-uninfected individuals. Clin. Infect. Dis. 2018;66(11):1762–1769. DOI: 10.1093/cid/cix1075. PMID: 29244126
45. Marcus J.L., Leyden W.A., Chao C.R., Chow F.C., Horberg M.A., Hurley L.B. et al. HIV infection and incidence of ischemic stroke. AIDS. 2014;28(13):1911–9. DOI: 10.1097/QAD.0000000000000352. PMID: 24937309
46. Gutierrez J., Albuquerque A.L.A., Falzon L. HIV infection as vascular risk: A systematic review of the literature and meta-analysis. PLoS One. 2017;12(5):e0176686. DOI: 10.1371/journal.pone.0176686. PMID: 28493892; PMCID: PMC5426615
47. Rasmussen L.D., Engsig F.N., Christensen H., Gerstoft J., Kronborg G., Pedersen C., Obel N. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS. 2011;25(13):1637–46. DOI: 10.1097/QAD.0b013e3283493fb0. PMID: 21646903
48. Vinikoor M.J., Napravnik S., Floris-Moore M., Wilson S., Huang D.Y., Eron J.J. Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res. Hum. Retroviruses. 2013;29(7):1068–74. DOI: 10.1089/aid.2012.0334. Epub 2013 May 10. PMID: 23565888; PMCID: PMC3685694
49. Marconi V.C., Duncan M.S., So–Armah K., Re V.L. 3rd., Lim J.K., Butt A.A. et al. Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (Veterans Aging Cohort Study). J. Am. Heart Assoc. 2018;7(10):e007792. DOI: 10.1161/JAHA.117.007792. PMID: 29720501; PMCID: PMC6015337
50. Triant V.A., Lee H., Hadigan C., Grinspoon S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodefi ciency virus disease. J. Clin. Endocrinol. Metab. 2007;92(7):2506–12. DOI: 10.1210/jc.2006-2190. PMID: 17456578; PMCID: PMC2763385
51. Benjamin L.A., Corbett E.L., Connor M.D., Mzinganjira H., Kampondeni S., Choko A. et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: A case-control study. Neurology. 2016;86(4):324–33. DOI: 10.1212/WNL.0000000000002278. PMID: 26683649; PMCID: PMC4776088
52. Sanders J.M., Steverson A.B., Pawlowski A.E., Schneider D., Achenbach C.J., Lloyd–Jones D.M., Feinstein M.J. Atrial arrhythmia prevalence and characteristics for human immunodefi ciency virus-infected persons and matched uninfected controls. PLoS One. 2018;13(3):e0194754. DOI: 10.1371/journal.pone.0194754. PMID: 29558525; PMCID: PMC5860783
53. Centers for Disease Control and Prevention et al. Diagnoses of HIV infection in the United States and dependent areas, 2017. HIV surveillance report. 2015;25:1–82.
54. Kossorotoff M., Touzé E., Godon–Hardy S., Serre I., Mateus C., Mas J.L., Zuber M. Cerebral vasculopathy with aneurysm formation in HIV–infected young adults. Neurology. 2006;66(7):1121–2. DOI: 10.1212/01.wnl.0000204188.85402.0c. PMID: 16606935
55. Amod F., Holla V.V., Ojha R., Pandey S., Yadav R., Pal P.K. A review of movement disorders in persons living with HIV. Parkinsonism Relat. Disord. 2023;114:105774. DOI: 10.1016/j.parkreldis.2023.105774. PMID: 37532621
56. Du Pasquier R.A., Corey S., Margolin D.H., Williams K., Pfi ster L.A., De Girolami U., Mac Key J.J., Wüthrich C., Joseph J.T., Koralnik I.J. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology. 2003;61(6):775–82. DOI: 10.1212/01.wnl.0000081306.86961.33. PMID: 14504320
57. Petiot P., Vighetto A., Charles N., Derex L., Trillet M., Aimard G. Isolated postural tremor revealing HIV-1 infection. J. Neurol. 1993;240(8):507–8. DOI: 10.1007/BF00874122. PMID: 8263559
58. Sporer B., Seelos K., Asmus F., Boetzel K., Pfi ster H.W. Posterior fossa tremor induced by HIV–associated progressive multifocal leukoencephalopathy. Eur. Neurol. 2005;53(2):96–7. DOI: 10.1159/000085507. PMID: 15855781
59. Cardoso F. HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs. 2002;16(10):663–8. DOI: 10.2165/00023210–200216100–00002. PMID: 12269860
60. Mattos J.P., Rosso A.L., Correa R.B., Novis S.A. Movement disorders in 28 HIV-infected patients. Arq. Neuropsiquiatr. 2002;60(3A):525–30. PMID: 12244384
61. Mirsattari S.M., Power C., Nath A. Parkinsonism with HIV infection. Mov. Disord. 1998;13(4):684–9. DOI: 10.1002/mds.870130413. PMID: 9686775
62. Uwishema O., Taylor C., Lawal L., Hamiidah N., Robert I., Nasir A., Chalhoub E., Sun J., Akin B.T., Adanur I., Mwazighe R.M., Onyeaka H. The syndemic burden of HIV/AIDS in Africa amidst the COVID-19 pandemic. Immun. Infl amm. Dis. 2022;10(1):26–32. DOI: 10.1002/iid3.544. PMID: 34606689; PMCID: PMC8652687
63. Singer E.J., Valdes–Sueiras M., Commins D., Levine A. Neurologic presentations of AIDS. Neurol. Clin. 2010;28(1):253–75. DOI: 10.1016/j.ncl.2009.09.018. PMID: 19932385; PMCID: PMC2806427
64. Kranick S.M., Nath A. Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Continuum (Minneap. Minn.). 2012;18(6 Infectious Disease):1319–37. DOI: 10.1212/01.CON.0000423849.24900.ec. PMID: 23221843; PMCID: PMC3760534
65. Okware S.I. (ed.). Advances in HIV and AIDS Control. BoD–Books on Demand, 2018.
66. Hogan C., Wilkins E. Neurological complications in HIV. Clin. Med. (Lond). 2011;11(6):571–5. DOI: 10.7861/clinmedicine.11-6-571. PMID: 22268312; PMCID: PMC4952339
67. UNAIDS. Global HIV & AIDS statistics — 2020 fact sheet. [Accessed 2021 May 1]. Available from: https://www.unaids.org/en/resources/fact–sheet.
68. Arts E.J., Hazuda D.J. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161. DOI: 10.1101/cshperspect.a007161.
69. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 2007;6(12):959–966. DOI: 10.1038/nrd2336
70. Deeks S.G., Lewin S.R., Havlir D.V. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533. DOI:10.1016/S0140–6736(13)61809–7.
71. Lundgren J.D., Babiker A.G., Gordin F. et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N. Engl. J. Med. 2015;373(9):795–807. DOI:10.1056/NEJMoa1506816
72. Carr A., Mackie N.E., Paredes R., Ruxrungtham K. HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective. Antiviral. Therapy. 2023;28(5). DOI:10.1177/13596535231201162
73. Lathouwers E., Wong E.Y., Brown K., Baugh B., Ghys A., Jezorwski J. et al.; AMBER and EMERALD Study Groups. Week 48 Resistance Analyses of the Once-Daily, Single–Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV–1 from the Phase III Randomized AMBER and EMERALD Trials. AIDS Res. Hum. Retroviruses. 2020;36(1):48–57. DOI: 10.1089/AID.2019.0111. Epub 2019 Oct 21. PMID: 31516033; PMCID: PMC6944133
74. Clutter D.S., Jordan M.R., Bertagnolio S., Shafer R.W. HIV-1 drug resistance and resistance testing. Infect. Genet. Evol. 2016;46:292-307. DOI: 10.1016/j.meegid.2016.08.031. PMID: 27587334; PMCID: PMC5136505
75. Cilento M.E., Kirby K.A., Sarafi anos S.G. Avoiding Drug Resistance in HIV Reverse Transcriptase. Chem. Rev. 2021;121(6):3271–3296. DOI: 10.1021/acs.chemrev.0c00967. PMID: 33507067; PMCID: PMC8149104
76. Iyidogan P., Anderson K.S. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses. 2014;6(10):4095–139. DOI: 10.3390/v6104095. PMID: 25341668; PMCID: PMC4213579
77. Muller J.T., Al Khalili Y. Emtricitabine. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 30969675
78. Saag M.S., Benson C.A., Gandhi R.T., Hoy J.F., Landovitz R.J. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA. 2018;320(4):379–396. DOI: 10.1001/jama.2018.8431. PMID: 30043070; PMCID: PMC6415748
79. Saag M.S. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin. Infect. Dis. 2006;42(1):126-31. DOI: 10.1086/498348. PMID: 16323102
80. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine. Prescrire Int. 2005 Apr;14(76):54–6. PMID: 15875341
81. Nishijima T., Gatanaga H., Oka S. Tenofovir nephrotoxicity among Asians living with HIV: review of the literature. Glob. Health Med. 2019;1(2):88–94. DOI: 10.35772/ghm.2019.01021. PMID: 33330761; PMCID: PMC7731346
82. Bierhoff M., Smolders E.J., Tarning J., Burger D.M., Spijker R., Rijken M.J. et al. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review. Antivir. Ther. 2019;24(7):529–540. DOI: 10.3851/IMP3341. PMID: 31868655
83. Li S., Jin J., Jiang Y., Shi J., Jiang X., Lin N., Ma Z. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate. Int. J. Antimicrob. Agents. 2023;61(3):106726. DOI: 10.1016/j.ijantimicag.2023.106726. PMID: 36646229
84. Fioroti C.E.A., Distenhreft J.I.Q., Paulino B.B., Lacchine K., Ramos D.R., Seguro A.C., Luchi W.M. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Rev. Inst. Med. Trop. Sao Paulo. 2022;64:e10. DOI: 10.1590/S1678-9946202264010. PMID: 35170711; PMCID: PMC8845457
85. Phuphuakrat A., Pasomsub E., Chantratita W., Mahasirimongkol S., Disthabanchong S., Sungkanuparph S., Kiertiburanakul S. Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate. J. Int. Assoc. Provid. AIDS Care. 2022;21:23259582221134751. DOI: 10.1177/23259582221134751. PMID: 36314476; PMCID: PMC9623366
86. Saeed M., Khan M., Nalamati J. Tenofovir-induced type II renal tubular acidosis and Fanconi syndrome: a case report. Chest. 2019;156(4):A1938.
87. Debeb S.G., Muche A.A., Kifl e Z.D., Sema F.D. Tenofovir disoproxil fumarate–associated renal dysfunction among adult people living with HIV at the university of gondar comprehensive specialized hospital, Northwest Ethiopia, 2019: A Comparative Retrospective Cohort Study. HIV AIDS (Auckl). 2021 13:491–503. DOI: 10.2147/HIV.S308339. PMID: 34007217; PMCID: PMC8123951
88. Ojeh B.V., Abah I.O., Ugoagwu P., Agaba PA., Agbaji O.O., Gyang S.S. Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients. Germs. 2018;8(2):67–76. DOI: 10.18683/germs.2018.1133. PMID: 29951379; PMCID: PMC6019953
89. Osuala E.C., Naidoo A., Dooley K.E., Naidoo K., Perumal R. Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection. Expert Rev. Clin. Pharmacol. 2023;16(10):939–957. DOI: 10.1080/17512433.2023.2251387. PMID: 37612306; PMCID: PMC10613124
90. Januszka J.E., Drwiega E.N., Badowski M.E. Bictegravir/ Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? HIV AIDS (Auckl). 2023;15:705–711. DOI: 10.2147/HIV.S385877. PMID: 38050483; PMCID: PMC10693755
91. Cohen C.J., Meyers J.L., Davis K.L. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8):e003028. DOI: 10.1136/bmjopen–2013–003028. PMID: 23906955; PMCID: PMC3733306
92. Clay P.G., Nag S., Graham C.M., Narayanan S. Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. Medicine (Baltimore). 2015;94(42):e1677. DOI: 10.1097/MD.0000000000001677. PMID: 26496277; PMCID: PMC4620781
93. Cento V., Perno C.F. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their effi cacy and safety. J. Glob. Antimicrob. Resist. 2020;20:228–237. DOI: 10.1016/j.jgar.2019.08.010. PMID: 31446092
Review
For citations:
Yusupov F.A., Ydyrysov I.T., Yuldashev A.A. Age, gender aspects of nervous system damage in hiv infection and modern treatment options. Clinical Medicine (Russian Journal). 2025;103(4):263-271. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-4-263-271
Views:
15
Email this article 